Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Advisory committee recommends approval of non-nicotine smoking cessation product

Dec. 13, 1996

NDA filed for Antizol

Dec. 13, 1996

New use claimed for olanzapine

Nov. 26, 1996

LecTec cleared to proceed with clinical testing of smoking cessation product

Nov. 22, 1996

Cocaine vaccine nearing clinic

Nov. 8, 1996

New therapeutic for smoking cessation to enter pivotal trials

Oct. 25, 1996

Nicotine inhaler for smoking cessation: Clinical trial results

Oct. 25, 1996

Cangene acquires iron chelator from Apotex

Oct. 18, 1996

Japanese scientists discover potential agent for siderosis

Oct. 11, 1996

Cocaine vaccine proven effective in animal model

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.